Comparing Antipsychotic Medications in LBD Over Time

Dementia With Lewy Bodies Clinical Trial

— CAMELOT  

Official title:

A Pragmatic Randomized Trial Comparing Antipsychotics in Lewy Body Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05590637
• Other study ID #: 22-0198H
• Status: Recruiting
• Phase: Phase 4
• Start date: April 22, 2022
• Est. completion date: April 2025

Study information

• Verified date: October 2023
• Source: The University of Texas Health Science Center at San Antonio
• Contact: Carolyn Paiz, BS
• Phone: 210-450-8830
• Email: paizc[@]uthscsa.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to determine whether treatment with pimavanserin or quetiapine is associated with a greater improvement in psychosis when used in a routine clinical setting to treat hallucinations and/or delusions due to Parkinson's disease (PD) or dementia with Lewy bodies (DLB) - collectively referred to as Lewy body disease (LBD).

Description:

Psychosis (hallucinations and delusions) is a common problem in Parkinson's disease (PD) and dementia with Lewy bodies (DLB). PD is a common neurodegenerative disorder that causes movement, cognitive, and psychiatric symptoms. DLB is a similar disorder, though causes more severe cognitive and psychiatric problems. Psychosis is highly prevalent among people with PD and DLB, often manifesting as visual hallucinations or paranoid delusions. Up to 60% of people with PD will experience psychosis over the course of their disease. Psychosis is associated with increased mortality, caregiver burden, and poorer quality of life. More study is needed to determine the best way to treat psychosis in PD and DLB. Currently, both quetiapine and pimavanserin are used in clinical practice for psychosis in PD and DLB. However, few comparison studies have been done and it is unclear if one medication is superior to the other. This will be a clinical trial comparing quetiapine and pimavanserin among patients with psychosis due to PD or DLB requiring initiation of a medication. Patients will be randomized to quetiapine or pimavanserin and improvement in psychosis at 6 months will be compared between the groups.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 94
• Est. completion date: April 2025
• Est. primary completion date: October 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patients seen in the neurology clinic at UT Health San Antonio
• Diagnosed with psychosis due to PD or DLB
• Requiring initiation of an antipsychotic medication
• Clinical equipoise between quetiapine and pimavanserin must exist
• The prescribing provider must be comfortable prescribing and managing both quetiapine and pimavanserin

Exclusion Criteria:

• Medical contraindication to either medication
• Caregiver unavailable to complete NPI-Q
• Currently taking an antipsychotic medication
• Prescribing provider unwilling to manage either medication

Related Conditions & MeSH terms

• Dementia With Lewy Bodies
• Lewy Body Disease
• Mental Disorders
• Parkinson Disease
• Parkinson's Disease Psychosis
• Psychotic Disorders

Intervention

Drug:
• Pimavanserin
Dosage choice and further medication management will be at the discretion of the treating clinician, per routine clinical practice.
• Quetiapine
Dosage choice and further medication management will be at the discretion of the treating clinician, per routine clinical practice.

Locations

Country	Name	City	State
United States	University Health System	San Antonio	Texas
United States	UT Health Science Center - San Antonio	San Antonio	Texas

Sponsors (2)

Lead Sponsor	Collaborator
The University of Texas Health Science Center at San Antonio	Alzheimer's Association

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Medication out-of-pocket cost	Amount of out of pocket costs spent on medications during the study	Baseline to 6 months
Other	NPI-Q caregiver portion	Change in the total of the caregiver distress items of the neuropsychiatric inventory. The scale contains 12 items, each scored from 0-5 (least to most distress). Possible scores Range from 0-60 with a lower score indicating less caregiver distress	Baseline to 6 months
Other	Patient contact	Number of between visit patient encounters (phone, EMR messages)	Baseline to 6 months
Primary	Neuropsychiatry Inventory Questionnaire (NPI-Q), Hallucinations + Delusions (H+D)	Change in the Hallucinations + Delusions sub-score of the neuropsychiatric inventory questionnaire. Each NPI-Q item is scored by severity (1-3), and distress to caregiver (0-5), then added together (range 0-8) with a higher score indicating greater severity.	Baseline to 6 months
Secondary	Neuropsychiatry Inventory Questionnaire (NPI-Q) total score	Change in the total neuropsychiatric inventory questionnaire score, which includes 12 items, each scored from 0-8 with a higher score indicating more severe symptoms.	Baseline to 6 months
Secondary	Neuropsychiatry Inventory Questionnaire (NPI-Q) (anxiety)	Change in the neuropsychiatric inventory questionnaire item for anxiety, scored from 0-8 with a higher score indicating more severe anxiety.	Baseline to 6 months
Secondary	Neuropsychiatry Inventory Questionnaire (NPI-Q) (agitation)	Change in the neuropsychiatric inventory questionnaire for agitation, scored from 0-8 with a higher score indicating more severe agitation.	Baseline to 6 months
Secondary	Neuropsychiatry Inventory Questionnaire (NPI-Q) (nighttime behaviors)	Change in the neuropsychiatric inventory questionnaire for sleep disturbance, scored from 0-8 with a higher score indicating more severe sleep disturbances.	Baseline to 6 months
Secondary	Mortality	Number of subjects who survived until the 6 month study assessment visit	6 months
Secondary	Time to discontinuation of per-protocol medication	Will examine whether participants continued the chosen medication until study completion or if they either discontinued the study medication or added the other study medication.	Baseline to 6 months
Secondary	MDS-UPDRS part 3	Unified Parkinson's Disease Rating Scale, motor score. The motor examination scale consists of 33 items graded 0-4 points with an overall possible score of 0-132 points. A higher score indicates a higher burden of motor symptoms.	Baseline to 6 months
Secondary	CGIC, PGIC, CGI-C:CVR	Clinician, patient, and caregiver global impressions of change. Each is a single item assessment rated from 1 (very much improved) to 7 (very much worse). A higher score indicates worsening symptoms.	Baseline to 6 months